Patrys advances RLS-2202 toward Phase 1 Clinical Trial
Filed with ASX · · 3 pages · English
Earlier from Patrys
- Appendix 4C - Quarterly - 31 March 2026
- $3.2 million Placement to Advance Clinical Trials
- Investor Presentation - Broker Meets Biotech
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
- Appendix 4D - Half Year Accounts - 31 December 2025
Later from Patrys
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Appendix 4C - Quarterly - 30 June 2026
- Investor Presentation - TechKnow Invest Roadshow
- Ethics Approval Secured for Phase 1A Clinical Trial
- Appendix 4E - Preliminary Final Report
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys